New treatment for myocardial diseases.

Treatment of myocardial diseases with renin-angiotensin system inhibitors and β-blockers has greatly contributed to improving prognosis. However, these treatments are non-specific, and with the exception of some treatments, radical treatments according to the cause of each disease have not been developed until recent years. But in the past decade, more specific and more upstream treatments based on the molecular mechanism of disease onset have been developed and are emerging. Some of the effects have been shown in clinical practice and already approved. This article outlines the mechanism of action and clinical data of novel therapeutic agents specific for myocardial diseases such as dilated cardiomyopathy, hypertrophic cardiomyopathy, Fabry disease, cardiac amyloidosis, and myocarditis. In the future, we hope that the molecular mechanisms will be further elucidated and new and upstream treatment methods will be developed.